Effect of Losartan on Prevention and Progression of Early Diabetic Nephropathy in American Indians With Type 2 Diabetes - Weil, E. Jennifer; Fufaa, Gudeta; Jones, Lois I.; Lovato, Tracy; Lemley, Kevin V.; Hanson, Robert L.; Knowler, William C.; Bennett, Peter H.; Yee, Berne; Myers, Bryan D.; Nelson, Robert G. (Diabetes (New York, N.Y.), 2013)
Keywords: Adult; Aged; Associated diseases and complications; Biological and medical sciences; Clinical trials; Complications and side effects; Development and progression; Diabetes; Diabetes Mellitus, Type 2 - complications; Diabetes Mellitus, Type 2 - drug therapy; Diabetes. Impaired glucose tolerance; Diabetic nephropathies; Diabetic Nephropathies - drug therapy; Diabetic Nephropathies - prevention & control; Dosage and administration; Endocrine pancreas. Apud cells (diseases); Endocrinopathies; Etiopathogenesis. Screening. Investigations. Target tissue resistance; Female; Humans; Indians, North American; Kidney diseases; Kidneys; Losartan; Losartan - therapeutic use; Male; Medical sciences; Middle Aged; Native North Americans; Nephrology. Urinary tract diseases; Original Research; Prevention; Risk factors; Side effects; Type 2 diabetes; Urinary system involvement in other diseases. Miscellaneous; Young Adult; United States; Endocrinopathy; Kidney disease; Type 2 diabetes; Imidazole derivatives; Tetrazole derivatives; Urinary system disease; Peptide hormone; Non peptide compound; Metabolic diseases; Prevention; Concomitant disease; Octapeptide; Renin angiotensin system; Biphenyl derivatives; Losartan; Indian; Diabetic nephropathy; Sartan derivatives; Angiotensin antagonist; Angiotensin II